单次注射临床相关剂量钆基对比剂后大鼠脑内钆潴留的长期评估
该研究将健康大鼠随机分为四组,分别单次静脉注射钆特酸葡胺、钆贝葡胺、钆双胺或等体积生理盐水,于注射后1个月和5个月处死,用电感耦合等离子体质谱测定小脑总钆浓度并用尺寸排阻色谱-电感耦合等离子体质谱分析钆形态。结果显示线性钆基对比剂(钆双胺、钆贝葡胺)残留钆浓度高于大环状钆特酸葡胺,且仅线性制剂出现与 macromolecules 结合的钆,5个月时该部分保持不变,可能代表永久沉积。
要点
- 单次临床相关剂量钆基对比剂即可在小脑检出钆残留,5个月时仍可测得。
- 钆双胺组小脑总钆浓度在1个月和5个月均显著高于钆特酸葡胺组(P<0.0001)。
- 仅线性制剂(钆贝葡胺和钆双胺)检出与 soluble macromolecules(>80 kDa)结合的钆,5个月时保持恒定。
诊断标准与关键数值
- 小脑总钆浓度(均值±标准差):钆双胺组M1为0.280±0.060 nmol/g、M5为0.193±0.023 nmol/g,均显著高于钆特酸葡胺组M1的0.019±0.004 nmol/g和M5的0.004±0.002 nmol/g(P<0.0001)。
- 钆贝葡胺组小脑总钆浓度M1为0.093±0.020 nmol/g、M5为0.067±0.013 nmol/g,两个时间点均显著低于钆双胺组(P<0.05)。
- M5时钆特酸葡胺组小脑总钆浓度亦显著低于钆贝葡胺组(P<0.05)。
- 水溶性组分形态分析:注射大环状钆特酸葡胺后5个月,钆仅以完整螯合形式检出;注射线性钆基对比剂(钆贝葡胺和钆双胺)后检出两种形式,即完整钆基对比剂和与 soluble macromolecules(above 80 kDa)结合的钆;完整钆基对比剂形式在M1至M5间被清除,而与 macromolecules 结合的钆在注射后5个月保持恒定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to investigate the presence and chemical forms of residual gadolinium (Gd) in rat brain after a single dose of Gd-based contrast agent.
METHODS: Four groups of healthy rats (2 sacrifice time-points, n = 10/group, 80 rats in total) were randomized to receive a single intravenous injection of 1 of the 3 Gd-based contrast agents (GBCAs) (gadoterate meglumine, gadobenate dimeglumine, or gadodiamide) or the same volume of 0.9% saline solution. The injected concentration was 0.6 mmol/kg, corresponding to a concentration of 0.1 mmol/kg in humans after body surface normalization between rats and humans (according to the US Food and Drug Administration recommendations). Animals were sacrificed at 2 washout times: 1 (M1) and 5 (M5) months after the injection. Total Gd concentrations were determined in cerebellum by inductively coupled plasma mass spectrometry. Gadolinium speciation was analyzed by size-exclusion chromatography coupled to inductively coupled plasma mass spectrometry after extraction from cerebellum.
RESULTS: A single injection of a clinically relevant dose of GBCA resulted in the detectable presence of Gd in the cerebellum 1 and 5 months after injection. The cerebellar total Gd concentrations after administration of the least stable GBCA (gadodiamide) were significantly higher at both time-points (M1: 0.280 ± 0.060 nmol/g; M5: 0.193 ± 0.023 nmol/g) than those observed for macrocyclic gadoterate (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: 0.093 ± 0.020 nmol/g; M5: 0.067 ± 0.013 nmol/g; P < 0.05) than the Gd concentration measured after injection of gadodiamide. At the 5-month time-point, the Gd concentration in the gadoterate group was also significantly lower than the Gd concentration in the gadobenate group (P < 0.05). Gadolinium speciation analysis of the water-soluble fraction showed that, after injection of the macrocyclic gadoterate, Gd was still detected only in its intact, chelated form 5 months after injection. In contrast, after a single dose of linear GBCAs (gadobenate and gadodiamide), 2 different forms were detected: intact GBCA and Gd bound to soluble macromolecules (above 80 kDa). Elimination of the intact GBCA form was also observed between the first and fifth month, whereas the amount of Gd present in the macromolecular fraction remained constant 5 months after injection.
CONCLUSIONS: A single injection of a clinically relevant dose of GBCA is sufficient to investigate long-term Gd retention in the cerebellar parenchyma. Administration of linear GBCAs (gadodiamide and gadobenate) resulted in higher residual Gd concentrations than administration of the macrocyclic gadoterate. Speciation analysis of the water-soluble fraction of cerebellum confirmed washout of intact GBCA over time. The quantity of Gd bound to macromolecules, observed only with linear GBCAs, remained constant 5 months after injection and is likely to represent a permanent deposition.
引用
- Strzeminska I, Factor C, Robert P, et al. Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents. Invest Radiol. 2020. PMID: 31917763. doi:10.1097/RLI.0000000000000623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。